Helsinn is a global biopharma company focused on addressing unmet needs in cancer. It has a commercial portfolio of cancer therapeutic and supportive care products underpinning the business as it progresses the research and development with an innovative pipeline of highly innovative oncology assets, building its fully integrated targeted therapies (Helsinn’s FITT strategy). Helsinn is guided by core values of respect, integrity and quality and the Group plays an active role in promoting social transformation in favour of people and the environment.